Cotton mouth, clinically termed xerostomia, is a condition marked by decreased salivary secretion, resulting in a dry, sticky feeling in the oral cavity. While occasional dryness may result from transient factors such as dehydration or anxiety, persistent xerostomia is a clinically significant issue that can severely impact oral health, speech, mastication, taste, and quality of life.
Saliva plays an indispensable role in oral homeostasis. It not only lubricates the mucosal surfaces and aids in digestion but also contributes to antimicrobial defense, buffering of acids, remineralization of enamel, and cleansing of the oral cavity. Hence, even a moderate reduction in salivary flow can have a disproportionate effect on dental and periodontal health.
Xerostomia arises either due to a reduction in salivary gland output or a change in the composition of saliva. The major salivary glands—parotid, submandibular, and sublingual—are primarily responsible for the secretion of serous and mucinous components, while numerous minor salivary glands maintain baseline mucosal lubrication.
Reduction in salivary flow (hyposalivation) may be:
Quantitative: objectively measurable decrease in saliva production (unstimulated flow <0.1 mL/min)
Qualitative: normal flow rate with altered composition or pH
Over 500 medications list dry mouth as a common side effect. These include:
Anticholinergics: e.g., atropine, scopolamine
Antidepressants: especially tricyclics (amitriptyline), SSRIs (fluoxetine)
Antihypertensives: beta-blockers, diuretics
Antihistamines: cetirizine, loratadine
Muscle relaxants and sedatives
Polypharmacy, especially among elderly patients, exponentially increases xerostomia risk.
Sjögren’s Syndrome: An autoimmune disease targeting exocrine glands, prominently affecting tear and saliva production.
Diabetes Mellitus: Causes dehydration and autonomic neuropathy affecting gland function.
Parkinson’s Disease and Alzheimer’s: Affect autonomic regulation of salivary flow.
HIV/AIDS: Associated with salivary gland disease and medication side effects.
Radiotherapy (especially head and neck): Causes irreversible damage to salivary acinar cells.
Chemotherapy: Temporarily affects salivary production and alters oral mucosa.
Tobacco and alcohol use
Caffeine consumption
Chronic mouth breathing (especially during sleep or nasal obstruction)
Dehydration and low water intake
Dryness and stickiness in the mouth
Difficulty in speaking, chewing, or swallowing
Burning or tingling sensation in the tongue (burning mouth syndrome)
Dysgeusia (altered taste) or ageusia (loss of taste)
Persistent thirst
Dry, shiny, and erythematous oral mucosa
Fissured or atrophic tongue
Dental caries, especially cervical or root surfaces
Halitosis (linked directly to VSCs and bacterial proliferation)
Angular cheilitis
Poor denture retention
Patients are often first to report symptoms of dry mouth. Standardized questionnaires, such as the SXI-D (Summated Xerostomia Inventory – Dutch version), are used to quantify subjective dryness.
Unstimulated Whole Saliva (UWS): Normal is 0.3–0.4 mL/min
Stimulated Whole Saliva (SWS): Normal is 1.0–2.0 mL/min
Measurements under 0.1 mL/min (UWS) are considered pathologic.
Sialography: Radiographic examination of salivary ducts.
Scintigraphy: Nuclear imaging for glandular function.
Ultrasound and MRI: Non-invasive methods to evaluate salivary gland architecture.
Labial salivary gland biopsy: Especially important in suspected Sjögren’s syndrome.
Management of cotton mouth focuses on:
Symptomatic relief
Prevention of oral complications
Restoration of glandular function (when possible)
Hydration: Regular water intake throughout the day
Humidification: Using room humidifiers, particularly at night
Avoiding xerogenic agents: Reduce caffeine, alcohol, and tobacco use
Chewing sugar-free gum or lozenges (xylitol-based)
Dietary modifications: Include crunchy fruits/vegetables to promote salivary reflex
Frequent oral rinsing with water or mild saline
Sialogogues:
Pilocarpine: Muscarinic agonist (5–10 mg, TID)
Cevimeline: Especially effective in Sjögren’s syndrome
Saliva Substitutes:
Over-the-counter gels, sprays, and rinses containing carboxymethylcellulose or mucopolysaccharides
Fluoride supplements: Prescription-strength fluoride toothpaste or varnishes to prevent decay
Frequent dental check-ups every 3–4 months
Custom fluoride trays for high-risk patients
Antifungal treatments for candidiasis, a common secondary infection
Antimicrobial rinses: e.g., chlorhexidine for plaque control
Coordinated care with specialists: rheumatology, endocrinology, neurology
Dose adjustment or substitution of xerogenic medications (when feasible)
Advanced trials are exploring stem cell-based regenerative therapies for irradiated or atrophic salivary glands.
Neurostimulation devices (such as electrostimulation mouthpieces) are in development to stimulate parasympathetic pathways responsible for salivation.
The introduction of beneficial strains such as Streptococcus salivarius is being researched to restore healthy oral microbiota and improve mucosal immunity.
Wearable biosensors for real-time monitoring of hydration and salivary composition are under clinical trial for chronic xerostomia management.
Dentists and hygienists must maintain a proactive protocol to manage xerostomic patients:
Avoid alcohol-based mouth rinses
Encourage use of non-sugar, pH-neutral oral care products
Educate on early signs of dental erosion or candidiasis
Implement dietary counseling to limit cariogenic intake
Although xerostomia is not life-threatening, its long-term impact on comfort, speech, nutritional intake, and oral health is significant. With proper diagnosis and multidisciplinary care, patients can manage symptoms effectively and prevent secondary complications.